Global Breast Biopsy Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type (Needle Breast Biopsy (Core Needle Biopsy, Fine Needle Aspiration Biopsy and Vacuum-Assisted Biopsy) and Open Surgical Breast Biopsy (Excisional Breast Biopsy and Incisional Breast Biopsy), Product, Guidance & Region - Industry Forecast From 2024 to 2029

Updated On: January, 2024
ID: 4101
Pages: 175

Global Breast Biopsy Market Size (2024 to 2029)

The global breast biopsy market is predicted to grow to USD 1358.96 Million by 2029 from USD 809.75 million in 2024, growing at a CAGR of 10.91% during the forecast period.

A breast biopsy is a test performed to remove tissue or fluid from a diseased area of the patient’s body while the extracted sample is further examined to check the presence of breast cancer. There are different types of biopsy procedures depending on the product, such as vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine-needle aspiration biopsy (FNAB), recommended by the doctor based on the location, size, and other characteristics of the breast abnormality. The various techniques of the biopsy market work quickly and are simple. As a result, the results are fast and accurate.

MARKET DRIVERS

The growing incidence of breast cancer primarily drives the global breast biopsy market growth.

An increase in breast cancer incidence in women, especially around the age of 40, and growth in awareness regarding breast cancer screening programs drive the market growth. According to the statistics of nationalbreastcancer.org, the United States had an estimated 276,480 invasive and 48,530 non-invasive breast cancer cases in 2020. They further stated that 1 in every eight women is likely to develop breast cancer in their lifetime in the United States.

The advancements in treatment procedures are propelling the breast biopsy market's growth.

There have been several developments in breast cancer treatment procedures in recent years. The development of targeted therapies and immunotherapies are examples of such advancements that have proven to improve patient outcomes. As a result, the demand for these treatment procedures is growing significantly with the increased breast cancer patient population. Furthermore, the growth of the global breast biopsy market is driven by improvements in traditional treatment modalities, such as surgery, radiation therapy and chemotherapy.

In addition, the emergence of technologically advanced and minimally invasive breast biopsy devices, growing awareness regarding breast biopsy across the world and the rising women's geriatric population boost the growth rate of the breast biopsy market. The growing awareness regarding the early detection of breast cancer, the increasing funding initiatives by several governments for breast cancer research, the rising trend towards minimally invasive surgical procedures and the availability of skilled healthcare professionals such as radiologists and pathologists in the developed and developing countries favor the market’s growth rate.

Furthermore, the growing prevalence of benign breast diseases such as fibroadenoma and cysts, growing demand for personalized medicine, an increasing number of initiatives to promote breast cancer screening, such as mammography screening programs, rising incidence of breast cancer in men, growing healthcare expenditure and increasing number of strategic partnerships and collaborations between healthcare providers and breast biopsy companies promote the market's growth rate. Factors include the growing demand for image-guided biopsies, such as ultrasound-guided and MRI-guided biopsies, rising adoption of breast tomosynthesis, favorable reimbursement policies for breast biopsy procedures, the growing demand for core needle biopsies and growing demand for liquid biopsy support the growth rate of the breast cancer market.

MARKET RESTRAINTS

The high costs associated with the procedure are one of the key factors hampering the growth of the breast biopsy market worldwide. In addition, the risk of infection due to improper care of breast biopsy cuts and wounds and uncertain regulatory guidelines for medical devices will likely limit the growth of the global breast biopsy market.

Impact of COVID-19 on the global breast biopsy market

COVID-19 has affected many sectors differently and has been declared a pandemic by World Health Organisation (WHO). The global economy was drastically decreased due to the coronavirus. The lockdown has influenced many industries in several ways; some industries were poorly impacted, and some gained profits. The Breast Biopsy Market is not an exception. The global breast biopsy market has gone through some rough times during the pandemic. Due to the lockdown, the patient flow has slowed since the restricted access to clinics and hospitals, which affected the Breast Biopsy Market. In addition, the fear in people about COVID-19 dragged people from getting diagnosed during the pandemic. Moreover, the breast biopsy devices required for breast biopsy treatment had not been delivered to the hospitals due to the pandemic, which hammered the market. But, after the pandemic, the market is getting profits. Therefore, the key players in the market are introducing new devices like Ultrasound Guided Breast Biopsy Devices to sustain the market competition. However, due to the reduced impact of COVID-19 and the growing adoption of new normalization among people, the global breast biopsy market is estimated to register a healthy CAGR during the forecast period.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2023 to 2029

Base Year

2023

Forecast Period

2024 to 2029

Segments Covered

By Product, Type, Guidance, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Market Leaders Profiled

Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.

 

SEGMENTAL ANALYSIS

Global Breast Biopsy Market Analysis By Product

Based on product, the biopsy needles segment had the largest share of the global breast biopsy market in 2023 and is expected to continue accounting for the leading share of the worldwide market during the forecast period. The rapid rise in the adoption of Biopsy needles in hospitals and clinics due to their advantages, like high sensitivity and specificity, drives the Biopsy needle segment. In addition, the advancements in technological devices are boosting the market. For example, Stryker PreciseCore needles allow sample acquisition with higher precision and considerably more negligible tissue damage risks. Moreover, the Biopsy Needles provide a more accurate assessment of breast mass than fine-needle aspiration. Therefore, the Guidance Systems segment is predominantly rising during the forecast period.

The guidance systems segment accounted for a considerable share of the global breast biopsy market in 2023 and is expected to grow considerably during the forecast period. The growth of the guidance systems segment is majorly driven by the increasing number of advancements in imaging technologies, such as ultrasound, MRI and stereotactic imaging, the growing adoption of minimally invasive surgical procedures such as ultrasound-guided and MRI-guided biopsies and the benefits associated with guidance systems such as real-time imaging guidance that helps healthcare professionals precisely locate and target the suspicious lesion.

Global Breast Biopsy Market Analysis By Type

Based on type, the vacuum-assisted biopsy segment accounted for the largest share of the global market in 2023. These devices can accurately locate the abnormality area without any difficulties, and the less-invasive nature of this technique is driving the vacuum-assisted biopsy segment. The increase in the usage of vacuum-assisted biopsy is boosting the segment. The fine needle aspiration biopsy segment is significantly growing during the forecast period. The demand for minimally invasive procedures and technological devices drives the needle aspiration biopsy segment.

Global Breast Biopsy Market Analysis By Guidance

The ultrasound segment is expected to be the fastest growing based on guidance in the global breast biopsy market during the forecast period. It is the quickest technique among all, which is driving the ultrasound-guided breast biopsy segment. It also decreases the need for ionizing radiation exposure and is opposite to the conventional mammography-guided stereotactic biopsy procedure. These are the factors boosting the ultrasound-guided breast biopsy segment growth.

On the other hand, the mammography-guided segment is estimated to grow at the highest CAGR during the forecast period owing to the accuracy and precision of this technique. The wide availability of mammography-guided stereotactic breast biopsy and increasing adoption of this technique by the many hospitals and diagnostic imaging centers globally further boost the segmental growth. The high success rate of mammography-guided stereotactic breast biopsy in obtaining tissue samples for accurate breast cancer diagnosis is another major factor propelling segmental growth.

REGIONAL ANALYSIS

The global breast biopsy market was dominated by North America, followed by Europe in 2023. Asia Pacific is expected to grow at the highest CAGR. During the forecast period, the North American breast biopsy market size is forecasted to grow at a CAGR of 10.5% due to the growing incidence of breast cancer in this region and the quick adoption of technological advancements. In this region, the United States market is predicted to account majority share during the forecast period. Breast cancer awareness is significantly growing in the U.S., and the ongoing technological advancements in treatment options are expected to fuel the U.S. breast biopsy market during the forecast period. Conversely, the Canadian market is projected to rise at a lucrative growth rate during the forecast period.

The breast biopsy market in Europe was the second-largest regional segment worldwide in 2023 and is estimated to register a healthy CAGR in the coming years. Stringent regulatory guidelines for breast cancer screening and diagnosis, rising emphasis on early detection and management of breast cancer and the growing geriatric population primarily propel the European market growth. The rising adoption of digital breast tomosynthesis (DBT) for improved breast cancer detection and growing emphasis on research and development for novel biopsy techniques and technologies further boost the growth rate of the European market. In Europe, countries such as the U.K. and Germany are expected to have lucrative growth opportunities during the forecast period in this regional market.

The Asia-Pacific breast biopsy market is forecasted to be the fastest-growing region in the global market during the forecast period. Rapidly growing incidence of breast cancer, particularly in countries like China and India, rising awareness about breast cancer screening and diagnosis among the general population, and increasing adoption of advanced medical technologies and infrastructure development majorly drive the APAC market growth. The growing healthcare expenditure and insurance coverage for breast cancer diagnosis and treatment and increasing collaborations between local and international organizations for breast cancer research and awareness further promote regional market growth. Across the globe, Asia has the highest percentage of an aging population. In addition, in the recent past, a significant spike in breast cancer incidence in this region is expected to drive this regional market during the forecast period.

The Latin American breast biopsy market is predicted to grow at a steady CAGR during the forecast period. The rising awareness about breast cancer and its early detection, growing adoption of breast cancer screening programs in urban areas, an increasing number of improvements in healthcare infrastructure and access to healthcare services contribute to the Latin American breast cancer market growth. In addition, the growing healthcare expenditure and insurance coverage for breast cancer diagnosis and treatment and rising emphasis on women's health and empowerment initiatives drive the regional market growth. Countries like Brazil and Mexico are projected to grow significantly during the forecast period in this region.

The breast biopsy market in MEA is forecasted to hold a moderate share of the global market in the coming years.

KEY MARKET PARTICIPANTS

The list of key players included in the report consists of Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.

RECENT MARKET DEVELOPMENTS

  • Hologic's Brevera Breast Biopsy System with CorLumina Imaging Technology gained European CE mark clearance in 2018. This technology enhances biopsy accuracy, patient satisfaction, and workflow in the biopsy suite with real-time imaging.
  • Hologic announced the introduction of their CorLumina Imaging Technology Brevera breast biopsy system for commercial access in the United States in 2017. It is developed with real-time imaging to boost the accuracy of the biopsy, improve patient experience and simplify the biopsy from start to end.
  • Mayo Clinic and Imago Systems Image Visualization Company cooperated on Breast Imaging in August 2019.
  • Dune Medical Devices announced the first-in-man test of their innovative biopsy instrument in March 2019. Dune Medical's Smart Biopsy is a percutaneous soft tissue biopsy tool that uses tiny key needle detectors to provide real-time electrical samples. These electrical pulses are compared to histological data to improve diagnosis and readout. The in-man stage marks the commencement of a more extensive, more thorough clinical study aimed at determining the specific tissue composition of the breast.
  • C. R. Bard Inc. was purchased by Becton, Dickinson, and Company (BD) for $16.0 billion. The merged firm is anticipated to enhance illness treatment and provide more convenience to healthcare professionals. Furthermore, C.R. Bard's robust product portfolio and innovation pipeline will expand BD's potential in fast-growing clinical areas and the combined company's growth opportunities outside of the United States.

DETAILED SEGMENTATION OF THE GLOBAL BREAST BIOPSY MARKET INCLUDED IN THIS REPORT

This market research report on the global breast biopsy market has been segmented and sub-segmented based on the product, type, guidance, and region.

By Product

  • Biopsy Needles
  • Guidance Systems
  • Biopsy Tables
  • Localization Wires 
  • Others

By Type

  • Needle Breast Biopsy 
    • Core Needle Biopsy
    • Fine Needle Aspiration Biopsy
    • Vacuum-Assisted Biopsy
  • Open Surgical Breast Biopsy 
    • Excisional Breast Biopsy
    • Incisional Breast Biopsy

By Guidance

  • Mammography-Guided Stereotactic Breast Biopsy
  • Ultrasound-Guided Breast Biopsy
  • MRI-Guided Breast Biopsy
  • Other Guidance Techniques

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Please wait. . . . Your request is being processed

Frequently Asked Questions

How much was the global breast biopsy market worth in 2023?

The global breast biopsy market was valued at USD 730.1 million in 2023.

Does this report include the impact of COVID-19 on the breast biopsy market?

COVID-19 has shown a significant negative impact on the breast biopsy market in the initial days and a detailed analysis of how has COVID-19 impacted the breast biopsy market is included in this report.

Which region had the largest share of the global breast biopsy market?

In 2023, the North American region accounted for the leading share of the breast biopsy market.

Who are the major players in the breast biopsy market?

Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL. are some of the notable players in the breast biopsy market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample